View Filing Data

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2014	May 01, 2014
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q1
Trading Symbol	TGTX
Entity Common Stock, Shares Outstanding		37,624,407
Entity Registrant Name	TG THERAPEUTICS, INC.
Entity Central Index Key	0001001316
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 49,596,327	$ 40,485,466
Short-term investment securities	3,901,783	0
Interest receivable	11,124	27,169
Prepaid research and development	2,418,995	1,742,824
Other current assets	359,885	47,804
Total current assets	56,288,114	42,303,263
Long-term investment securities	1,001,858	4,918,897
Equipment, net	8,177	5,718
Goodwill	799,391	799,391
Other assets	76,415	85,121
Total assets	58,173,955	48,112,390
Current liabilities:
Notes payable, current portion	0	677,778
Accounts payable and accrued expenses	1,639,114	4,764,502
Accrued compensation	197,250	532,500
Current portion of deferred revenue	152,381	152,381
Interest payable	0	190,017
Total current liabilities	1,988,745	6,317,178
Deferred revenue, net of current portion	1,638,095	1,676,191
Notes payable, less current portion, at fair value	115,554	64,529
Total liabilities	3,742,394	8,057,898
Commitments and contingencies
Equity:
Preferred stock, $0.001 par value per share (10,000,000 shares authorized, 0 issued and outstanding as of March 31, 2014 and December 31, 2013)	0	0
Common stock, $0.001 par value per share (500,000,000 shares authorized, 37,525,527 and 34,336,235 shares issued, 37,484,218 and 34,294,926 shares outstanding at March 31, 2014 and December 31, 2013, respectively)	37,526	34,336
Contingently issuable shares	6	6
Additional paid-in capital	101,579,618	79,658,490
Treasury stock, at cost, 41,309 shares at March 31, 2014 and December 31, 2013	(234,337)	(234,337)
Deficit accumulated in the development stage	(46,951,252)	(39,404,003)
Total equity	54,431,561	40,054,492
Total liabilities and equity	$ 58,173,955	$ 48,112,390

Condensed Consolidated Balance Sheets [Parenthetical] - $ / shares	Mar. 31, 2014	Dec. 31, 2013
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, Shares Authorized	500,000,000	500,000,000
Common stock, shares issued	37,525,527	34,336,235
Common stock, shares outstanding	37,484,218	34,294,926
Treasury stock	41,309	41,309

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		28 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
License revenue	$ 38,095	$ 38,095	$ 209,524
Research and development:
Noncash stock expense associated with in-licensing agreement	0	0	16,875,000
Noncash compensation	1,901,610	354,703	3,398,938
Other research and development	2,508,258	1,215,202	19,153,884
Total research and development	4,409,868	1,569,905	39,427,822
General and administrative:
Noncash compensation	2,329,828	1,530,774	9,544,324
Other general and administrative	903,524	651,457	5,683,265
Total general and administrative	3,233,352	2,182,231	15,227,589
Impairment of in-process research and development	0	0	3,902,300
Total costs and expenses	7,643,220	3,752,136	58,557,711
Operating loss	(7,605,125)	(3,714,041)	(58,348,187)
Other (income) expense:
Interest income	(13,474)	(1,502)	(60,083)
Other income	(95,427)	0	(476,553)
Interest expense	226,340	231,472	2,092,069
Change in fair value of notes payable	(175,315)	(270,400)	(5,136,138)
Total other income	(57,876)	(40,430)	(3,580,705)
Loss before income taxes	(7,547,249)	(3,673,611)	(54,767,482)
Income taxes	0	0	330,000
Consolidated net loss	(7,547,249)	(3,673,611)	(55,097,482)
Net loss attributable to non-controlling interest	0	0	(8,146,230)
Net loss attributable to TG Therapeutics, Inc. and Subsidiaries	$ (7,547,249)	$ (3,673,611)	$ (46,951,252)
Basic and diluted net loss per common share (in dollars per share)	$ (0.25)	$ (0.17)
Weighted average shares used in computing basic and diluted net loss per common share (in shares)	30,091,000	21,953,803

Condensed Consolidated Statement of Equity - 3 months ended Mar. 31, 2014 - USD ($)	Total	Preferred Stock [Member]	Common Stock [Member]	Contingently Issuable Share [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Accumulated Deficit during Development Stage [Member]
Balance at Dec. 31, 2013	$ 40,054,492	$ 0	$ 34,336	$ 6	$ 79,658,490	$ (234,337)	$ (39,404,003)
Balance (in shares) at Dec. 31, 2013		0	34,336,235			41,309
Issuance of common stock in connection with exercise of warrants	901,472		$ 397		901,075
Issuance of common stock in connection with exercise of warrants (in shares)			396,483
Issuance of restricted stock	0		$ 90		(90)
Issuance of restricted stock (in shares)			90,000
Issuance of common stock in public offering (net of offering costs of $1,344,440)	16,791,408		$ 2,703		16,788,705
Issuance of common stock in public offering (net of offering costs of $1,344,440) (in shares)			2,702,809
Compensation in respect of restricted stock granted to employees, directors and consultants	4,231,438				4,231,438
Net loss	(7,547,249)						(7,547,249)
Balance at Mar. 31, 2014	$ 54,431,561	$ 0	$ 37,526	$ 6	$ 101,579,618	$ (234,337)	$ (46,951,252)
Balance (in shares) at Mar. 31, 2014		0	37,525,527			41,309

Condensed Consolidated Statement of Equity [Parenthetical]	3 Months Ended
	Mar. 31, 2014 USD ($)
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	$ 1,344,440

Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		28 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Consolidated net loss	$ (7,547,249)	$ (3,673,611)	$ (55,097,482)
Adjustments to reconcile consolidated net loss to cash used in operating activities:
Gain on settlement of notes payable	(95,427)	0	(95,427)
Stock compensation expense	4,231,438	1,885,477	12,943,262
Noncash stock expense associated with in-licensing agreement	0	0	16,875,000
Impairment of in-process research and development	0	0	3,902,300
Depreciation	706	115	2,068
Amortization of premiums on investment securities, net	15,255	0	16,230
Change in fair value and accrued interest of notes payable	51,025	(54,838)	(3,179,243)
Changes in assets and liabilities, net of effects of acquisition:
Increase in other current assets	(988,252)	(580,691)	(2,688,111)
(Increase) decrease in accrued interest receivable	16,045	0	(11,124)
Decrease (increase) in other assets	8,706	0	(76,415)
Increase (decrease) in accounts payable and accrued expenses	(3,888,453)	240,985	1,150,219
(Decrease) increase in interest payable	(94,590)	15,910	40,584
(Decrease) increase in deferred revenue	(38,095)	(38,095)	1,790,476
Net cash used in operating activities	(8,328,891)	(2,204,748)	(24,427,663)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of equipment	(3,165)	0	(10,245)
Investment in held-to-maturity long-term securities	0	0	(4,919,871)
Cash acquired in connection with acquisition	0	0	10,386
Net cash used in investing activities	(3,165)	0	(4,919,730)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from the exercise of warrants	901,472	936,920	3,182,245
Payments of notes payable	(677,778)	0	(877,779)
Proceeds from sale of common stock, net	17,219,223	0	64,692,185
Proceeds from sale of preferred stock, net	0	0	12,257,309
Offering costs paid	0	0	(75,903)
Purchase of treasury stock	0	0	(234,337)
Net cash provided by financing activities	17,442,917	936,920	78,943,720
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	9,110,861	(1,267,828)	49,596,327
Cash and cash equivalents at beginning of period	40,485,466	16,455,995	0
CASH AND CASH EQUIVALENTS AT END OF PERIOD	49,596,327	15,188,167	49,596,327
NONCASH TRANSACTIONS
Conversion of notes payable to preferred stock	0	0	55,271
Accrued financing costs	$ 427,815	$ 0	$ 488,953

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Description of Business

We are a biopharmaceutical company focused on the acquisition, development and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. We aim to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Currently, we are developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. We are also developing TGR-1202, an orally available PI3K delta inhibitor.

The accompanying unaudited condensed consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they may not include all of the information and footnotes required by GAAP for complete financial statements. All adjustments that are, in the opinion of management, of a normal recurring nature and are necessary for a fair presentation of the consolidated financial statements have been included. Nevertheless, these consolidated financial statements should be read in conjunction with the audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2013. The results of operations for the three months ended March 31, 2014 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.

Liquidity and Capital Resources

We have incurred operating losses since our inception and expect to continue to incur operating losses for the foreseeable future and may never become profitable. As of March 31, 2014, we have an accumulated deficit of $46,951,252.

Our major sources of cash have been proceeds from the private placement and public offering of equity securities, the upfront payment from our Sublicense Agreement with Ildong Pharmaceutical Co. Ltd. (“Ildong”), and warrant exercises. We have not yet commercialized any of our drug candidates and cannot be sure if we will ever be able to do so. Even if we commercialize one or more of our drug candidates, we may not become profitable. Our ability to achieve profitability depends on a number of factors, including our ability to obtain regulatory approval for our drug candidates, successfully complete any post-approval regulatory obligations and successfully commercialize our drug candidates alone or in partnership. We may continue to incur substantial operating losses even if we begin to generate revenues from our drug candidates.

In March 2014, we raised approximately $16.8 million, net of underwriting discounts and offering expenses of approximately $1.3 million, in an underwritten public offering. See Note 5 for additional information.

As of March 31, 2014, we had $54,511,092 in cash, cash equivalents, investment securities, and interest receivable. We currently anticipate that our cash and cash equivalents will be sufficient to fund our anticipated operating cash requirements for at least 24 months from March 31, 2014. The actual amount of cash that we will need to operate is subject to many factors, including, but not limited to, the timing, design and conduct of clinical trials for our drug candidates. We are dependent upon significant future financing to provide the cash necessary to execute our current operations, including the commercialization of any of our drug candidates.

Our common stock is listed on the NASDAQ Capital Market and trades under the symbol “TGTX.”

Recently Issued Accounting Standards

Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to the consolidated financial statements of the Company.

Cash and Cash Equivalents

We treat liquid investments with original maturities of less than three months when purchased as cash and cash equivalents.

Revenue Recognition

We recognize license revenue in accordance with the revenue recognition guidance of the FASB Accounting Standards Codification, or Codification. We analyzed each element of our licensing agreement to determine the appropriate revenue recognition. The terms of the license agreement may include payments to us of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. We recognize revenue from upfront payments over the period of significant involvement under the related agreements unless the fee is in exchange for products delivered or services rendered that represent the culmination of a separate earnings process and no further performance obligation exists under the contract. We recognize milestone payments as revenue upon the achievement of specified milestones only if (1) the milestone payment is non-refundable, (2) substantive effort is involved in achieving the milestone, (3) the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement of the milestone, and (4) the milestone is at risk for both parties. If any of these conditions are not met, we defer the milestone payment and recognize it as revenue over the estimated period of performance under the contract.

Research and Development Costs

Generally, research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are delivered or the related services are performed, subject to an assessment of recoverability. We make estimates of costs incurred in relation to external clinical research organizations, or CROs, and clinical site costs. We analyze the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and estimates must be made and used in determining the accrued balance and expense in any accounting period. We review and accrue CRO expenses and clinical trial study expenses based on work performed and rely upon estimates of those costs applicable to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under these contracts may be uneven, and depend on factors such as the achievement of certain events, the successful recruitment of patients, the completion of portions of the clinical trial or similar conditions. The objective of our policy is to match the recording of expenses in our financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified in the specific clinical study or trial contract.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. If the likelihood of realizing the deferred tax assets or liability is less than “more likely than not,” a valuation allowance is then created.

We, and our subsidiaries, file income tax returns in the U.S. Federal jurisdiction and in various states. We have tax net operating loss carryforwards that are subject to examination for a number of years beyond the year in which they were generated for tax purposes. Since a portion of these net operating loss carryforwards may be utilized in the future, many of these net operating loss carryforwards will remain subject to examination.

We recognize interest and penalties related to uncertain income tax positions in income tax expense.

Stock-Based Compensation

We recognize all share-based payments to employees and to non-employee directors as compensation for service on our board of directors as compensation expense in the consolidated financial statements based on the fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

For share-based payments to consultants and other third-parties, compensation expense is determined at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting date. The awards to consultants and other third-parties are then revalued, or the total compensation is recalculated based on the then current fair value, at each subsequent reporting date.

Basic and Diluted Net Loss Per Share of Common Stock

Basic net income (loss) per share of Common Stock is calculated by dividing net loss applicable to the Common Stock by the weighted-average number of the Common Stock outstanding for the period. Diluted net loss per share of Common Stock is the same as basic net loss per share of Common Stock since potentially dilutive securities from stock options, stock warrants and convertible preferred stock would have an antidilutive effect either because the Company incurred a net loss during the period presented or because such potentially dilutive securities were out of the money and the Company realized net income during the period presented. The amounts of potentially dilutive securities excluded from the calculation were 10,103,105 and 10,415,859 at March 31, 2014 and 2013, respectively. During the three months ended March 31, 2014 and 2013, the Company incurred a net loss; therefore, all of the dilutive securities are excluded from the computation of diluted earnings per share.

Goodwill

Goodwill is reviewed for impairment annually, or when events arise that could indicate that an impairment exists. We test for goodwill impairment using a two-step process. The first step compares the fair value of the reporting unit with the unit's carrying value, including goodwill. When the carrying value of the reporting unit is greater than fair value, the unit’s goodwill may be impaired, and the second step must be completed to measure the amount of the goodwill impairment charge, if any. In the second step, the implied fair value of the reporting unit’s goodwill is compared with the carrying amount of the unit’s goodwill. If the carrying amount is greater than the implied fair value, the carrying value of the goodwill must be written down to its implied fair value. We will continue to perform impairment tests annually, at December 31, and whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable.

CASH AND CASH EQUIVALENTS

3 Months Ended

Mar. 31, 2014

Cash and Cash Equivalents [Abstract]

Cash and Cash Equivalents Disclosure [Text Block]

NOTE 2 – CASH AND CASH EQUIVALENTS

	March 31, 2014		December 31, 2013

Money market funds	$	15,587,596	$	554,069
Checking and bank deposits		34,008,731		39,931,397
Total	$	49,596,327	$	40,485,466

- Definition

The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.

+ References + Details

INVESTMENT SECURITIES

3 Months Ended

Mar. 31, 2014

Investments, Debt and Equity Securities [Abstract]

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

NOTE 3 – INVESTMENT SECURITIES

We record our investments as either held-to-maturity or available-for-sale. Held-to-maturity investments are recorded at amortized cost.

The following tables summarize our investment securities at March 31, 2014 and December 31, 2013:

	March 31, 2014
	Amortized cost, as adjusted		Gross unrealized holding gains		Gross unrealized holding losses		Estimated fair value
Short-term investments:
Obligations of domestic governmental agencies (maturing between January 2015 and February 2015) (held-to-maturity)	$	3,901,783	$	1,654	$	—	$	3,903,437

Long-term investments:
Obligations of domestic governmental agencies (maturing April 2015) (held-to-maturity)	$	1,001,858	$	482	$	—	$	1,002,340

	December 31, 2013
	Amortized cost, as adjusted		Gross unrealized holding gains		Gross unrealized holding losses		Estimated fair value
Long-term investments:
Obligations of domestic governmental agencies (maturing between January 2015 and April 2015) (held-to-maturity)	$	4,918,897	$	—	$	650	$	4,918,247

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

FAIR VALUE MEASUREMENTS

3 Months Ended

Mar. 31, 2014

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

NOTE 4 – FAIR VALUE MEASUREMENTS

We measure certain financial assets and liabilities at fair value on a recurring basis in the financial statements. The hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires financial assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:

⋅

Level 1 – quoted prices in active markets for identical assets and liabilities;

⋅

Level 2 – inputs other than Level 1 quoted prices that are directly or indirectly observable; and

⋅

Level 3 – unobservable inputs that are not corroborated by market data.

As of March 31, 2014 and December 31, 2013, the fair values of cash and cash equivalents, and notes and interest payable approximate their carrying value.

Upon the merger between Manhattan and Ariston Pharmaceuticals, Inc. (“Ariston”) in March 2010, Ariston issued $15,452,793 of five-year 5% notes payable (the “5% Notes”) in satisfaction of several note payable issuances. The 5% Notes and accrued and unpaid interest thereon are convertible at the option of the holder into Common Stock at the conversion price of $1,125 per share. Ariston agreed to make quarterly payments on the 5% Notes equal to 50% of the net product cash flow received from the exploitation or commercialization of Ariston’s product candidates, AST-726 and AST-915. The Company has no obligations under the 5% Notes aside from a) 50% of the net product cash flows from Ariston’s product candidates, if any, payable to noteholders; and b) the conversion feature, discussed above.

In connection with the reverse merger transaction (the “Exchange Transaction”) with TG Biologics, Inc. (“TGBio”) in December 2011, the Company performed a valuation of the assets and liabilities of Manhattan immediately prior to the transaction. The cumulative liability including accrued and unpaid interest of the 5% Notes was approximately $16,876,000 immediately prior to the Exchange Transaction, and $18,614,000 at December 31, 2013 and $18,840,359 at March 31, 2014. As the 5% Notes are tied directly to net product cash flows derived from the preexisting products of Ariston, the 5% Notes and accrued interest were recorded at fair value of $3,287,700 as of the date of the Exchange Transaction. No payments have been made on the 5% Notes as of March 31, 2014.

We elected the fair value option for valuing the 5% Notes upon the Exchange Transaction with TG Bio. We elected the fair value option in order to reflect in our financial statements the assumptions that market participants use in evaluating these financial instruments.

As of December 31, 2013, as a result of expiring intellectual property rights and other factors, it was determined that net product cash flows from AST-726 were unlikely. As we have no other obligations under the 5% Notes aside from the net product cash flows and the conversion feature, the conversion feature was used to estimate the 5% Notes’ fair value as of March 31, 2014 and December 31, 2013. The assumptions, assessments and projections of future revenues are subject to uncertainties, are difficult to predict and require significant judgment. The use of different assumptions, applying different judgment to inherently subjective matters and changes in future market conditions could result in significantly different estimates of fair value and the differences could be material to our consolidated financial statements.

The following table provides the fair value measurements of applicable financial liabilities as of March 31, 2014 and December 31, 2013:

	Financial liabilities at fair value as of March 31, 2014
	Level 1		Level 2		Level 3		Total

5% Notes	$	—	$	—	$	115,554	$	115,554
Totals	$	—	$	—	$	115,554	$	115,554

	Financial liabilities at fair value as of December 31, 2013
	Level 1		Level 2		Level 3		Total

5% Notes	$	—	$	—	$	64,529	$	64,529
Totals	$	—	$	—	$	64,529	$	64,529

The Level 3 amounts above represent the fair value of the 5% Notes and related accrued interest.

The following table summarizes the changes in Level 3 instruments during the three months ended March 31, 2014:

Fair value at December 31, 2013	$	64,529
Interest accrued on face value of 5% Notes		226,340
Change in fair value of Level 3 liabilities		(175,315)
Fair value at March 31, 2014	$	115,554

The change in the fair value of the Level 3 liabilities is reported in other (income) expense in the accompanying condensed consolidated statement of operations.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

STOCKHOLDERS' EQUITY

3 Months Ended

Mar. 31, 2014

Stockholders' Equity Note [Abstract]

Shareholders Equity and Share-based Payments [Text Block]

NOTE 5 - STOCKHOLDERS' EQUITY

Preferred Stock

Our amended and restated certificate of incorporation authorizes the issuance of up to 10,000,000 shares of preferred stock, $0.001 par value, with rights senior to those of our common stock, issuable in one or more series. Upon issuance, our board of directors can determine the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock.

Common Stock

Our amended and restated certificate of incorporation authorizes the issuance of up to 500,000,000 shares of $0.001 par value common stock.

On March 11, 2014, we announced the pricing of an underwritten sale of 2,702,809 shares of our Common Stock at a price of $6.71 per share for gross proceeds of approximately $18.1 million. Total net proceeds from this offering were approximately $16.8 million, net of underwriting discounts and offering expenses of approximately $1.3 million. The shares were sold under a shelf registration statement on Form S-3 (File No. 333-189015) that was previously filed and declared effective by the SEC on June 17, 2013.

We currently have one shelf registration statement on Form S-3 filed and declared effective by the SEC (File No. 333-189015). Subsequent to the March 2014 offering, there remains available under this shelf registration statement up to approximately $117 million of Common Stock. We may offer the securities under our shelf registration statement from time to time in response to market conditions or other circumstances if we believe such a plan of financing is in the best interests of our stockholders. We believe that this shelf registration statement provides us with the flexibility to raise additional capital to finance our operations as needed.

Equity Incentive Plans

Shares available for the issuance of stock options or other stock-based awards under our stock option and incentive plans were 1,017,793 shares at March 31, 2014.

Stock Options

The following table summarizes stock option activity for the three months ended March 31, 2014:

	Number of shares		Weighted- average exercise price		Weighted- average Contractual Term		Aggregate Intrinsic Value
					(in years)
Outstanding at December 31, 2013		46,591	$	46.37		8.50	$	—
Granted		—		—
Exercised		—		—
Forfeited		—		—
Expired		(359)		4,640.63
Outstanding at March 31, 2014		46,232	$	10.70		8.32	$	115,000

Vested and expected to vest at March 31, 2014		9,232	$	35.94		8.23	$	22,500
Exercisable at March 31, 2014		9,232	$	35.94		8.23	$	22,500

As of March 31, 2014, the total compensation cost related to unvested time-based option awards not yet recognized was $0. This amount does not include, as of March 31, 2014, 37,000 non-employee options outstanding which are milestone-based and vest upon certain corporate milestones. Stock-based compensation will be measured and recorded if and when a milestone occurs.

Restricted Stock

Certain employees, directors and consultants have been awarded restricted stock. The restricted stock vesting consists of milestone and time-based vesting. The following table summarizes restricted share activity for the three months ended March 31, 2014:

	Number of Shares		Weighted Average Grant Date Fair Value
Outstanding at December 31, 2013		7,034,957	$	4.60
Granted		90,000		6.60
Vested		(197,500)		5.52
Forfeited		—		—
Outstanding at March 31, 2014		6,927,457	$	4.60

Total expense associated with restricted stock grants was $4,231,438 during the three months ended March 31, 2014. As of March 31, 2014, there was approximately $7,492,000 of total unrecognized compensation cost related to unvested time-based restricted stock, which is expected to be recognized over a weighted-average period of 1.7 years. This amount does not include, as of March 31, 2014, 1,779,710 shares of restricted stock outstanding which are milestone-based and vest upon certain corporate milestones; and 2,412,375 shares of restricted stock outstanding issued to non-employees. Milestone-based non-cash compensation expense will be measured and recorded if and when a milestone occurs.

Warrants

The following table summarizes warrant activity for the three months ended March 31, 2014:

	Warrants		Weighted- average exercise price		Aggregate Intrinsic Value
Outstanding at December 31, 2013		5,718,947	$	1.34	$	14,809,030
Issued		—		—
Exercised		(396,483)		2.27
Expired		(9,795)		20.92
Outstanding at March 31, 2014		5,312,669	$	1.24	$	30,087,064

Stock-Based Compensation

The fair value of stock options granted is estimated at the date of grant using the Black-Scholes pricing model. The expected term of options granted is derived from historical data and the expected vesting period. Expected volatility is based on the historical volatility of our common stock. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. We have assumed no expected dividend yield, as dividends have never been paid to stock or option holders and will not be paid for the foreseeable future. The Company did not grant any stock options during the three months ended March 31, 2014.

The following table summarizes stock-based compensation expense information about stock options and restricted stock for the three months ended March 31, 2014 and 2013:

	Three months ended March 31, 2014		Three months ended March 31, 2013
Stock-based compensation expense associated with restricted stock	$	4,231,438	$	1,885,477
Stock-based compensation expense associated with option grants		—		—
	$	4,231,438	$	1,885,477

NOTES PAYABLE

3 Months Ended

Mar. 31, 2014

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

NOTE 6 – NOTES PAYABLE

The following is a summary of notes payable:

	March 31, 2014						December 31, 2013
	Current portion, net		Non- current portion, net		Total		Current portion, net		Non- current portion, net		Total
Convertible 5% Notes Payable	$	-	$	115,554	$	115,554	$	-	$	64,529	$	64,529
ICON Convertible Note		-		-		-		677,778		-		677,778
Total	$	-	$	115,554	$	115,554	$	677,778	$	64,529	$	742,307

Convertible 5% Notes Payable

On March 8, 2010, Manhattan entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among Manhattan, Ariston and Ariston Merger Corp., a Delaware corporation and wholly-owned subsidiary of Manhattan (the "Merger Sub"). Pursuant to the terms and conditions set forth in the Merger Agreement, on March 8, 2010, the Merger Sub merged with and into Ariston (the "Merger"), with Ariston being the surviving corporation of the Merger. As a result of the Merger, Ariston became a wholly-owned subsidiary of Manhattan.

The 5% Notes and accrued and unpaid interest thereon are convertible at the option of the holder into Common Stock at the conversion price of $1,125 per share. Ariston agreed to make quarterly payments on the 5% Notes equal to 50% of the net product cash flow received from the exploitation or commercialization of Ariston’s product candidates, AST-726 and AST-915. We have no obligation under the 5% Notes aside from a) 50% of the net product cash flows from Ariston’s product candidates, if any, payable to noteholders; and b) the conversion feature, discussed above. Interest accrues monthly, is added to principal on an annual basis, every March 8, and is payable at maturity, which is March 8, 2015.

In connection with the Exchange Transaction in December 2011, we performed a valuation of the assets and liabilities of Manhattan immediately prior to the transaction. The cumulative liability including accrued and unpaid interest of these notes was approximately $16,876,000 immediately prior to the Exchange Transaction, and $18,840,359 at March 31, 2014 and $18,614,000 at December 31, 2013. As the 5% Notes are tied directly to net product cash flows derived from the preexisting products of Ariston, the 5% Notes and accrued interest were recorded at fair value of $3,287,700 as of the date of the Exchange Transaction (See Note 4 for further details). No payments have been made on the 5% Notes as of March 31, 2014.

ICON Convertible Note Payable

As of December 31, 2013 the principal amount of the Amended ICON Note was $677,778, of which the entire balance had been classified as current and was reflected as notes payable, current portion, in the accompanying consolidated balance sheet. Interest payable on the Amended ICON Note was $190,017 as of December 31, 2013, and was reflected as interest payable in the accompanying consolidated balance sheet. As of December 31, 2013, the ICON Note was in default as we did not make the balloon payment due on January 31, 2012, or any subsequent payments. In January 2014, we entered into a settlement and release agreement with ICON related to this note, under which we agreed to pay $772,369 in full settlement of the principal and interest due on this note, resulting in a gain of $95,427.

LICENSE AGREEMENTS

3 Months Ended

Mar. 31, 2014

License Agreement [Abstract]

License Agreement Disclosure [Text Block]

NOTE 7 – LICENSE AGREEMENTS

In November 2012, we entered into an exclusive (within the territory) sublicense agreement with Ildong relating to the development and commercialization of TG-1101 in South Korea and Southeast Asia. Under the terms of the sublicense agreement, Ildong has been granted a royalty bearing, exclusive right, including the right to grant sublicenses, to develop and commercialize TG-1101 in South Korea, Taiwan, Singapore, Indonesia, Malaysia, Thailand, Philippines, Vietnam, and Myanmar.

An upfront payment of $2,000,000, which was received in December 2012, net of $330,000 of income tax withheld, is being recognized as license revenue on a straight-line basis over the life of the agreement, which is through the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated, and represents the estimated period over which we will have certain ongoing responsibilities under the sublicense agreement. We recorded license revenue of approximately $38,000 for each of the three months ended March 31, 2014 and 2013, and, at March 31, 2014 and December 31, 2013, have deferred revenue of approximately $1,790,000 and $1,829,000, respectively, associated with this $2,000,000 payment (approximately $152,000 of which has been classified in current liabilities at March 31, 2014).

We may receive up to an additional $5.0 million in payments upon the achievement of pre-specified milestones. In addition, upon commercialization, Ildong will make royalty payments to us on net sales of TG-1101 in the sublicense territory.

RELATED PARTY TRANSACTIONS

3 Months Ended

Mar. 31, 2014

NOTE 8 – RELATED PARTY TRANSACTIONS

On January 30, 2012, we entered into an exclusive license agreement with LFB Biotechnologies, GTC Biotherapeutics and LFB/GTC LLC, all wholly-owned subsidiaries of LFB Group, relating to the development of ublituximab (the “License Agreement”). In connection with the License Agreement LFB Group was issued 5,000,000 shares of Common Stock, and a warrant to purchase 2,500,000 shares of Common Stock at a purchase price of $0.001 per share. In addition, on November 9, 2012 we nominated Dr. Yann Echelard to our Board of Directors as LFB Group’s nominee. LFB Group maintains the right to nominate a board member until such time as LFB Group owns less than 10% of the outstanding Common Stock.

Under the terms of the License Agreement, we utilize LFB Group for certain development and manufacturing services. We incurred approximately $183,000 and $357,000 in expenses for such services during the three months ended March 31, 2014 and 2013, respectively, which have been included in other research and development expenses in the accompanying consolidated statements of operations. As of March 31, 2014 and December 31, 2013, we had approximately $137,000 and $1,745,000, respectively, recorded in accounts payable related to the License Agreement. In conjunction with the development and manufacturing services discussed above, certain agreements between us and LFB Group require payments in advance of services performed or goods delivered. Accordingly, as of March 31, 2014 and December 31, 2013, we recorded $2,187,081 and $1,629,340, respectively, in prepaid research and development for such advance payments.

In March 2014, we entered into a shared services agreement with Opus Point Partners Management, LLC (“Opus”) in which the parties agree to share a rented facility and costs for certain other services. Michael S. Weiss, our Executive Chairman and Interim Chief Executive Officer, is a Managing Member of Opus. During the three months ended March 31, 2014, we incurred expenses of approximately $7,000 related to this agreement. In addition, as of March 31, 2014, we recorded approximately $92,000 in other current assets for certain receivables and prepaid items pertaining to Opus.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

Business Description [Policy Text Block]

Description of Business

Liquidity Disclosure [Policy Text Block]

Liquidity and Capital Resources

Our common stock is listed on the NASDAQ Capital Market and trades under the symbol “TGTX.”

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Issued Accounting Standards

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

We treat liquid investments with original maturities of less than three months when purchased as cash and cash equivalents.

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

Research and Development Expense, Policy [Policy Text Block]

Research and Development Costs

Income Tax, Policy [Policy Text Block]

Income Taxes

We recognize interest and penalties related to uncertain income tax positions in income tax expense.

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Stock-Based Compensation

Earnings Per Share, Policy [Policy Text Block]

Basic and Diluted Net Loss Per Share of Common Stock

Impairment Of Tangible and Intangible Asset Including Goodwill [Policy Text Block]

Goodwill

CASH AND CASH EQUIVALENTS (Tables)

3 Months Ended

Mar. 31, 2014

Cash and Cash Equivalents [Abstract]

Schedule of Cash and Cash Equivalents [Table Text Block]

	March 31, 2014		December 31, 2013

Money market funds	$	15,587,596	$	554,069
Checking and bank deposits		34,008,731		39,931,397
Total	$	49,596,327	$	40,485,466

INVESTMENT SECURITIES (Tables)

3 Months Ended

Mar. 31, 2014

Investments, Debt and Equity Securities [Abstract]

Held-to-maturity Securities [Table Text Block]

The following tables summarize our investment securities at March 31, 2014 and December 31, 2013:

	March 31, 2014
	Amortized cost, as adjusted		Gross unrealized holding gains		Gross unrealized holding losses		Estimated fair value
Short-term investments:
Obligations of domestic governmental agencies (maturing between January 2015 and February 2015) (held-to-maturity)	$	3,901,783	$	1,654	$	—	$	3,903,437

Long-term investments:
Obligations of domestic governmental agencies (maturing April 2015) (held-to-maturity)	$	1,001,858	$	482	$	—	$	1,002,340

	December 31, 2013
	Amortized cost, as adjusted		Gross unrealized holding gains		Gross unrealized holding losses		Estimated fair value
Long-term investments:
Obligations of domestic governmental agencies (maturing between January 2015 and April 2015) (held-to-maturity)	$	4,918,897	$	—	$	650	$	4,918,247

- Definition

Tabular disclosure of all investments in certain debt and equity securities for which the entity has the positive intent and ability to hold until maturity.

+ References + Details

FAIR VALUE MEASUREMENTS (Tables)

3 Months Ended

Mar. 31, 2014

Fair Value Disclosures [Abstract]

Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block]

The following table provides the fair value measurements of applicable financial liabilities as of March 31, 2014 and December 31, 2013:

	Financial liabilities at fair value as of March 31, 2014
	Level 1		Level 2		Level 3		Total

5% Notes	$	—	$	—	$	115,554	$	115,554
Totals	$	—	$	—	$	115,554	$	115,554

	Financial liabilities at fair value as of December 31, 2013
	Level 1		Level 2		Level 3		Total

5% Notes	$	—	$	—	$	64,529	$	64,529
Totals	$	—	$	—	$	64,529	$	64,529

Change In Level Three Fair Value During Period [Table Text Block]

The following table summarizes the changes in Level 3 instruments during the three months ended March 31, 2014:

Fair value at December 31, 2013	$	64,529
Interest accrued on face value of 5% Notes		226,340
Change in fair value of Level 3 liabilities		(175,315)
Fair value at March 31, 2014	$	115,554

STOCKHOLDERS' EQUITY (Tables)

3 Months Ended

Mar. 31, 2014

Stockholders' Equity Note [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

The following table summarizes stock option activity for the three months ended March 31, 2014:

	Number of shares		Weighted- average exercise price		Weighted- average Contractual Term		Aggregate Intrinsic Value
					(in years)
Outstanding at December 31, 2013		46,591	$	46.37		8.50	$	—
Granted		—		—
Exercised		—		—
Forfeited		—		—
Expired		(359)		4,640.63
Outstanding at March 31, 2014		46,232	$	10.70		8.32	$	115,000

Vested and expected to vest at March 31, 2014		9,232	$	35.94		8.23	$	22,500
Exercisable at March 31, 2014		9,232	$	35.94		8.23	$	22,500

Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]

The following table summarizes restricted share activity for the three months ended March 31, 2014:

	Number of Shares		Weighted Average Grant Date Fair Value
Outstanding at December 31, 2013		7,034,957	$	4.60
Granted		90,000		6.60
Vested		(197,500)		5.52
Forfeited		—		—
Outstanding at March 31, 2014		6,927,457	$	4.60

Schedule Of Warrants Activity [Table Text Block]

The following table summarizes warrant activity for the three months ended March 31, 2014:

	Warrants		Weighted- average exercise price		Aggregate Intrinsic Value
Outstanding at December 31, 2013		5,718,947	$	1.34	$	14,809,030
Issued		—		—
Exercised		(396,483)		2.27
Expired		(9,795)		20.92
Outstanding at March 31, 2014		5,312,669	$	1.24	$	30,087,064

Schedule Of Share Based Compensation Expense [Table Text Block]

The following table summarizes stock-based compensation expense information about stock options and restricted stock for the three months ended March 31, 2014 and 2013:

	Three months ended March 31, 2014		Three months ended March 31, 2013
Stock-based compensation expense associated with restricted stock	$	4,231,438	$	1,885,477
Stock-based compensation expense associated with option grants		—		—
	$	4,231,438	$	1,885,477

NOTES PAYABLE (Tables)

3 Months Ended

Mar. 31, 2014

Debt Disclosure [Abstract]

Schedule of Debt [Table Text Block]

The following is a summary of notes payable:

	March 31, 2014						December 31, 2013
	Current portion, net		Non- current portion, net		Total		Current portion, net		Non- current portion, net		Total
Convertible 5% Notes Payable	$	-	$	115,554	$	115,554	$	-	$	64,529	$	64,529
ICON Convertible Note		-		-		-		677,778		-		677,778
Total	$	-	$	115,554	$	115,554	$	677,778	$	64,529	$	742,307

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) - USD ($)		3 Months Ended
	Mar. 11, 2014	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Significant Accounting Policies [Line Items]
Deficit accumulated in development stage		$ 46,951,252		$ 39,404,003
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		10,103,105	10,415,859
Period Anticipated Sufficient To Fund Operating Cash Flow		24 months
Cash, Cash Equivalents, and Short-term Investments, Total		$ 54,511,092
Cash Equivalents Maturity Period		less than three months
Net Proceeds From Issuance Of Common Stock		$ 16,800,000
Underwriting discounts and offering expenses	$ 1,300,000	$ 1,300,000

- Definition

Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.

+ References + Details

CASH AND CASH EQUIVALENTS (Details) - USD ($)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012	Nov. 30, 2011
Cash and Cash Equivalents [Line Items]
Money market funds	$ 15,587,596	$ 554,069
Checking and bank deposits	34,008,731	39,931,397
Total	$ 49,596,327	$ 40,485,466	$ 15,188,167	$ 16,455,995	$ 0

INVESTMENT SECURITIES (Details) - US Government Agencies Debt Securities [Member] - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Short-term Investments [Member]
Schedule of Held-to-maturity Securities [Line Items]
Amortized cost, as adjusted	$ 3,901,783
Gross unrealized holding gains	1,654
Gross unrealized holding losses	0
Estimated fair value	3,903,437
Other Long-term Investments [Member]
Schedule of Held-to-maturity Securities [Line Items]
Amortized cost, as adjusted	1,001,858	$ 4,918,897
Gross unrealized holding gains	482	0
Gross unrealized holding losses	0	650
Estimated fair value	$ 1,002,340	$ 4,918,247

FAIR VALUE MEASUREMENTS (Details) - USD ($)	Mar. 31, 2014	Dec. 31, 2013
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
5% Notes	$ 115,554	$ 64,529
Totals	115,554	64,529
Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
5% Notes	0	0
Totals	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
5% Notes	0	0
Totals	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
5% Notes	115,554	64,529
Totals	$ 115,554	$ 64,529

FAIR VALUE MEASUREMENTS (Details 1)	3 Months Ended
FAIR VALUE MEASUREMENTS (Details 1)	Mar. 31, 2014 USD ($)
Fair Value, Measurement Changes In Level 3 Instruments [Line Items]
Fair value at December 31, 2013	$ 64,529
Interest accrued on face value of 5% Notes	226,340
Change in fair value of Level 3 liabilities	(175,315)
Fair value at March 31, 2014	$ 115,554

FAIR VALUE MEASUREMENTS (Details Textual) - USD ($)	1 Months Ended
FAIR VALUE MEASUREMENTS (Details Textual) - USD ($)	Mar. 31, 2010	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2011
Fair Value Measurement [Line Items]
Debt Instrument, Interest Rate, Effective Percentage		5.00%	5.00%
Long-term Debt, Gross		$ 18,840,359	$ 18,614,000	$ 16,876,000
Debt Instrument, Fair Value Disclosure				$ 3,287,700
Manhattan and Ariston Pharmaceuticals Merger [Member]
Fair Value Measurement [Line Items]
Notes Issued	$ 15,452,793
Debt Instrument, Interest Rate, Effective Percentage	5.00%
Debt Instrument, Convertible, Conversion Price	$ 1,125
Percentage Of Cash Proceeds From Operation To Repay Convertible Debt	50.00%
Debt Instrument Maturity Period	5 years

STOCKHOLDERS' EQUITY (Details) - USD ($)	3 Months Ended	12 Months Ended
STOCKHOLDERS' EQUITY (Details) - USD ($)	Mar. 31, 2014	Dec. 31, 2013
Equity Incentive Plans Stock Option Activity [Line Items]
Number of shares, Outstanding Beginning Balance	46,591
Number of shares, Granted	0
Number of shares, Exercised	0
Number of shares, Forfeited	0
Number of shares, Expired	(359)
Number of shares, Outstanding Ending Balance	46,232	46,591
Number of shares, Vested and expected to vest at March 31, 2014	9,232
Number of shares, Exercisable at March 31, 2014	9,232
Weighted - average exercise price, Outstanding Beginning Balance	$ 46.37
Weighted - average exercise price, Granted	0
Weighted - average exercise price, Exercised	0
Weighted - average exercise price, Forfeited	0
Weighted - average exercise price, Expired	4,640.63
Weighted - average exercise price, Outstanding Ending Balance	10.70	$ 46.37
Weighted - average exercise price, Vested and expected to vest at March 31, 2014	35.94
Weighted - average exercise price, Exercisable at March 31, 2014	$ 35.94
Weighted - average Contractual Term, Outstanding at ending period	8 years 3 months 25 days	8 years 6 months
Weighted - average Contractual Term, Vested and expected to vest at March 31, 2014	8 years 2 months 23 days
Weighted - average Contractual Term, Exercisable at March 31, 2014	8 years 2 months 23 days
Aggregate Intrinsic Value, Outstanding Beginning Balance	$ 0
Aggregate Intrinsic Value, Outstanding Ending Balance	115,000	$ 0
Aggregate Intrinsic Value, Vested and expected to vest at March 31, 2014	22,500
Aggregate Intrinsic Value, Exercisable at March 31, 2014	$ 22,500

STOCKHOLDERS' EQUITY (Details 1) - Restricted Stock [Member]	3 Months Ended
	Mar. 31, 2014 $ / shares shares
Equity Incentive Plans Restricted Stock Activity [Line Items]
Number of Shares, Outstanding at December 31, 2013 \| shares	7,034,957
Number of Shares, Granted \| shares	90,000
Number of Shares, Vested \| shares	(197,500)
Number of Shares, Forfeited \| shares	0
Number of Shares, Outstanding at March 31, 2014 \| shares	6,927,457
Weighted Average Grant Date Fair Value, Outstanding at December 31, 2013 \| $ / shares	$ 4.60
Weighted Average Grant Date Fair Value, Granted \| $ / shares	6.60
Weighted Average Grant Date Fair Value, Vested \| $ / shares	5.52
Weighted Average Grant Date Fair Value, Forfeited \| $ / shares	0
Weighted Average Grant Date Fair Value, Outstanding at March 31, 2014 \| $ / shares	$ 4.60

STOCKHOLDERS' EQUITY (Details 2)	3 Months Ended
STOCKHOLDERS' EQUITY (Details 2)	Mar. 31, 2014 USD ($) $ / shares shares
Equity Incentive Plans Warrant Activity [Line Items]
Warrants, Outstanding at December 31, 2013 \| shares	5,718,947
Warrants, Issued \| shares	0
Warrants, Exercised \| shares	(396,483)
Warrants, Expired \| shares	(9,795)
Warrants, Outstanding at March 31, 2014 \| shares	5,312,669
Weighted - average exercise price of Warrants, Outstanding at December 31, 2013 \| $ / shares	$ 1.34
Weighted - average exercise price of Warrants, Issued \| $ / shares	0
Weighted - average exercise price of Warrants, Exercised \| $ / shares	2.27
Weighted - average exercise price of Warrants, Expired \| $ / shares	20.92
Weighted - average exercise price of Warrants, Outstanding at March 31, 2014 \| $ / shares	$ 1.24
Aggregate Intrinsic Value of Warrants, Outstanding at December 31, 2013 \| $	$ 14,809,030
Aggregate Intrinsic Value of Warrants, Outstanding at March 31, 2014 \| $	$ 30,087,064

STOCKHOLDERS' EQUITY (Details 3) - USD ($)	3 Months Ended		28 Months Ended
STOCKHOLDERS' EQUITY (Details 3) - USD ($)	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Stock Based Compensation [Line Items]
Stock compensation expense	$ 4,231,438	$ 1,885,477	$ 12,943,262
Restricted Stock [Member]
Stock Based Compensation [Line Items]
Stock-based compensation expense associated with restricted stock	4,231,438	1,885,477
Employee Stock Option [Member]
Stock Based Compensation [Line Items]
Stock-based compensation expense associated with option grants	$ 0	$ 0

STOCKHOLDERS' EQUITY (Details Textual) - USD ($)		3 Months Ended		28 Months Ended
STOCKHOLDERS' EQUITY (Details Textual) - USD ($)	Mar. 11, 2014	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Dec. 31, 2013
Stockholders Equity [Line Items]
Preferred stock, shares authorized		10,000,000		10,000,000	10,000,000
Common Stock, Shares Authorized		500,000,000		500,000,000	500,000,000
Preferred stock, par value (in dollars per share)		$ 0.001		$ 0.001	$ 0.001
Common stock, par value (in dollars per share)		$ 0.001		$ 0.001	$ 0.001
Share Based Compensation Non Employee Stock Options Outstanding		37,000		37,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance		46,232		46,232	46,591
Shares available from Shelf Registration Statement		$ 117,000,000
Stock Issued During Period, Shares, New Issues	2,702,809
Share Price	$ 6.71
Proceeds From Issuance Of Common Stock	$ 18,100,000	17,219,223	$ 0	$ 64,692,185
Net Proceeds From Shares New Issues Over-Allotments	16,800,000
Underwriting discounts and offering expenses	$ 1,300,000	1,300,000
Share-based Compensation, Total		4,231,438	$ 1,885,477	12,943,262
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options		$ 0		$ 0
Common Stock [Member]
Stockholders Equity [Line Items]
Stock Issued During Period, Shares, New Issues		2,702,809
Non Employee Restricted Stock [Member]
Stockholders Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance		2,412,375		2,412,375
Corporate Milestone [Member]
Stockholders Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance		1,779,710		1,779,710
Restricted Stock [Member]
Stockholders Equity [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition		1 year 8 months 12 days
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized		$ 7,492,000		$ 7,492,000
Share-based Compensation, Total		$ 4,231,438
Equity Incentive Plans [Member]
Stockholders Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		1,017,793		1,017,793

NOTES PAYABLE (Details) - USD ($)	Mar. 31, 2014	Dec. 31, 2013
Notes Payable [Line Items]
Notes payable, Current portion, net	$ 0	$ 677,778
Notes payable, Non-current portion, net	115,554	64,529
Total	115,554	742,307
Convertible Notes [Member]
Notes Payable [Line Items]
Notes payable, Current portion, net	0	0
Notes payable, Non-current portion, net	115,554	64,529
Total	115,554	64,529
ICON Convertible Note [Member]
Notes Payable [Line Items]
Notes payable, Current portion, net	0	677,778
Notes payable, Non-current portion, net	0	0
Total	$ 0	$ 677,778

NOTES PAYABLE (Details Textual) - USD ($)		1 Months Ended
NOTES PAYABLE (Details Textual) - USD ($)	Mar. 08, 2010	Jan. 31, 2014	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2011
Notes Payable [Line Items]
Long-term Debt, Gross			$ 18,840,359	$ 18,614,000	$ 16,876,000
Notes Payable, Current, Total			$ 0	677,778
Debt Instrument, Fair Value Disclosure					$ 3,287,700
Convertible Notes Payable [Member]
Notes Payable [Line Items]
Debt Instrument, Convertible, Conversion Price	$ 1,125
Debt Instrument, Maturity Date	Mar. 08, 2015
Icon Clinical Research [Member]
Notes Payable [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	5.00%		5.00%
Interest Payable				$ 190,017
Debt Instrument Settlement Of Principal And Interest		$ 772,369
Debt Instrument Gain On Settlement		$ 95,427
Ariston [Member]
Notes Payable [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	5.00%
Percentage Of Cash Proceeds From Operation To Repay Interest On Convertible Debt	50.00%

LICENSE AGREEMENTS (Details Textual) - USD ($)	3 Months Ended		12 Months Ended	28 Months Ended
LICENSE AGREEMENTS (Details Textual) - USD ($)	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2012	Mar. 31, 2014	Dec. 31, 2013
License Agreement [Line Items]
License revenue	$ 38,095	$ 38,095		$ 209,524
Deferred Revenue	1,790,000			1,790,000	$ 1,829,000
Additional Amount Receivable On Achievement Of Pre Specified Milestones	5,000,000
Income taxes	$ 0	$ 0	$ 330,000	330,000
Business Acquisition Purchase Agreement Period Description	license revenue on a straight-line basis over the life of the agreement, which is through the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated
Upfront Fee Received From Sub License			$ 2,000,000
Deferred Revenue, Current	$ 152,381			$ 152,381	$ 152,381

RELATED PARTY TRANSACTIONS (Details Textual) - USD ($)		1 Months Ended	3 Months Ended		28 Months Ended
RELATED PARTY TRANSACTIONS (Details Textual) - USD ($)	Mar. 11, 2014	Jan. 30, 2012	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Dec. 31, 2013
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, New Issues	2,702,809
Other research and development			$ 2,508,258	$ 1,215,202	$ 19,153,884
Prepaid Research and Development			2,418,995		2,418,995	$ 1,742,824
Opus [Member]
Related Party Transaction [Line Items]
Costs and Expenses, Related Party			7,000
Accounts and Other Receivables, Net, Current			92,000		92,000
LFB Group [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, New Issues		5,000,000
Other research and development			183,000	$ 357,000
Accounts Payable			137,000		137,000	1,745,000
Number Of Common Stock Shares Granted In Connection With License Agreement By Issue Of Warrants		2,500,000
Common Stock Purchase Price Per Share		$ 0.001
Prepaid Research and Development			$ 2,187,081		$ 2,187,081	$ 1,629,340